{"id":4736,"date":"2026-05-13T01:15:00","date_gmt":"2026-05-12T23:15:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=4bbec671f7e21ce5f884067260b6f788"},"modified":"2026-05-13T01:15:00","modified_gmt":"2026-05-12T23:15:00","slug":"diamedica-therapeutics-to-participate-in-the-2026-rbc-capital-markets-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=4736","title":{"rendered":"DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference"},"content":{"rendered":"<p>MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that its President and CEO, Rick Pauls, will participate in a fireside chat at the upcoming 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19<sup>th<\/sup> in New York City.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260512758158\/en\/2803236\/5\/DiaMedica-Logo_-_email_signature.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260512758158\/en\/2803236\/22\/DiaMedica-Logo_-_email_signature.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260512758158\/en\/2803236\/5\/DiaMedica-Logo_-_email_signature.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260512758158\/en\/2803236\/21\/DiaMedica-Logo_-_email_signature.jpg\" \/><\/a><p>\n<b>Fireside Chat Details<\/b><\/p><p class=\"bwmarginl1\">\n<b>Date &amp; Time:<\/b> Tuesday, May 19, 2026 | 4:05-4:30 PM ET\n<br\/><b>Location: <\/b>InterContinental New York Barclay NY | 111 E 48<sup>th<\/sup> Street, New York, NY 10017<\/p><p>\nMr. Pauls will also be available for one-on-one meetings with investors during the conference.<\/p><p>\n<b><i>About DiaMedica Therapeutics Inc.\n<br\/><\/i><\/b>DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica\u2019s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company\u2019s website at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.diamedica.com&amp;esheet=54534512&amp;newsitemid=20260512758158&amp;lan=en-US&amp;anchor=www.diamedica.com&amp;index=1&amp;md5=09ea857d1d790aa5ce56962e568a643e\" rel=\"nofollow\" shape=\"rect\">www.diamedica.com<\/a>.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nScott Kellen\n<br\/>Chief Financial Officer\n<br\/>Phone: (763) 496-5118\n<br\/><a  href=\"mailto:skellen@diamedica.com\" rel=\"nofollow\" shape=\"rect\">skellen@diamedica.com<\/a><\/p><p>\n<b>For Investor Inquiries:<\/b><br\/>Mike Moyer\n<br\/>Managing Director, LifeSci Advisors, LLC\n<br\/>Phone: (617) 308-4306\n<br\/><a  href=\"mailto:mmoyer@lifesciadvisors.com\" rel=\"nofollow\" shape=\"rect\">mmoyer@lifesciadvisors.com<\/a><\/p><p>\n<b>Media Contact:<\/b><br\/>Madelin Hawtin\n<br\/>LifeSci Communications\n<br\/><a  href=\"mailto:mhawtin@lifescicomms.com\" rel=\"nofollow\" shape=\"rect\">mhawtin@lifescicomms.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211;DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that its P&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4736","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/4736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4736"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/4736\/revisions"}],"predecessor-version":[{"id":4737,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/4736\/revisions\/4737"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}